Pantoprazol +pharma (Pantoprazole Sodium Sesquihydrate)

Pantoprazole Sodium Sesquihydrate, the active ingredient in Pantoprazol +pharma, is a proton pump inhibitor presented as a tablet for oral use. It reduces stomach acid production and is used to treat acid‑related disorders such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults.

GNH USA supplies Pantoprazol +pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazole is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related conditions: - Gastro‑oesophageal reflux disease (GERD): provides relief of heartburn and promotes healing of the oesophageal lining. - Erosive oesophagitis: accelerates endoscopic healing of erosive lesions. - Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence. - Zollinger‑Ellison syndrome: controls gastric acid hypersecretion associated with this rare endocrine disorder.

Pantoprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: usually self‑limiting. - Nausea: occasional and transient. - Abdominal pain: mild discomfort. - Flatulence: increased intestinal gas. - Constipation: occasional bowel habit change.

Serious or Rare Side Effects: - Severe hypersensitivity: rash, angio‑edema, or anaphylaxis. - Clostridioides difficile infection: persistent diarrhoea with abdominal cramping. - Low magnesium (hypomagnesemia): muscle cramps, tremor, or cardiac arrhythmia. - Acute interstitial nephritis: renal impairment with eosinophilia. - Fracture risk: reduced bone mineral density with long‑term use. - Liver enzyme elevation: hepatitis‑like picture in rare cases.

When prescribing Pantoprazole, clinicians should consider several safety aspects: - Renal impairment: dose adjustment may be required in severe kidney disease. - Hepatic impairment: monitor liver function in patients with existing liver disease. - Long‑term therapy: assess need for periodic review to avoid unnecessary prolonged use. - Osteoporosis risk: evaluate bone health in patients at high fracture risk. - Drug interactions: review concomitant medications for potential CYP‑mediated effects. - Store at ambient temperature: keep below 25°C, retain original packaging, and protect from moisture.

Pantoprazole may affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Antifungal agents (ketoconazole, itraconazole): reduced absorption due to higher gastric pH. - HIV protease inhibitors (atazanavir, nelfinavir): decreased plasma concentrations. - Clopidogrel: diminished antiplatelet effect, increasing cardiovascular risk.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring closer coagulation monitoring. - Digoxin: slight rise in serum levels, monitor for toxicity. - Methotrexate (high dose): reduced renal clearance, monitor renal function and drug levels.